---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013383"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:51:59.846886+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports 100% 6-month and 96% 12-month ablation success in nPulse study

## Summary
- Sustained 100% procedural success at 6 months (95/95 evaluable patients by holter).
- Sustained 96% procedural success at 12 months (51/53 evaluable patients).
- 90% Kaplan-Meier freedom from AF/AFL/AT at one year; low SAE rate of 1.7% (3/177).
- Efficient procedure: left atrial dwell 18.6 min, total procedure 60.2 min, fluoroscopy 9.4 min.
- Data presented at Heart Rhythm 2026 by Dr. Vivek Reddy; 177 patients treated across 7 European sites.

## SEC filing metadata
- accession: 0001437749-26-013383
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926013383/0001437749-26-013383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926013383/plse20260424_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013383
- JSON: https://secwatch.observer/filing/0001437749-26-013383.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.